"Over the last decades, various new agents have been developed for the treatment of metastatic breast cancer and overall survival of these patients has increased. The role of chemotherapy in the treatment of metastatic breast cancer is well established. Bevacizumab is a potent antiangiogenic agent active in many solid tumors. Three randomised clinical trials (E2100, AVADO and RIBBON I) proved the benefit of chemotherapy, especially a combination of taxanes and bevacizumab, as the first line treatment of metastatic breast cancer. The combination improved patient progression-free survival in all trials with no impact on the known toxic effects of taxanes. This may be a potent treatment option particularly for patients with triple negative breast cancer, and a potentially less toxic alternative to combination chemotherapy."@en . . "karcinom prsu; antiangiogenn\u00ED l\u00E1tky; bevacizumab"@en . . "Klinick\u00E1 onkologie" . "RIV/00209805:_____/11:#0000195!RIV12-MZ0-00209805" . . . . "Avastin v l\u00E9\u010Db\u011B karcinomu prsu" . "RIV/00209805:_____/11:#0000195" . . . . "2" . "CZ - \u010Cesk\u00E1 republika" . "Avastin v l\u00E9\u010Db\u011B karcinomu prsu" . . "[93DD3067B509]" . "Avastin v l\u00E9\u010Db\u011B karcinomu prsu"@cs . . . "24" . "Avastin v l\u00E9\u010Db\u011B karcinomu prsu"@cs . "5"^^ . . "Avastin in the treatment of breast cancer"@en . "187694" . "0862-495X" . . "http://www.linkos.cz/files/klinicka-onkologie/161/3761.pdf" . . . "1"^^ . "Pacientky s metastatick\u00FDm karcinomem prsu p\u0159e\u017E\u00EDvaj\u00ED v posledn\u00EDch desetilet\u00EDch signifikantn\u011B d\u00E9le, a to hlavn\u011B d\u00EDky nov\u00FDm l\u00E9\u010Debn\u00FDm mo\u017Enostem. Chemoterapie je jednou z hlavn\u00EDch l\u00E9\u010Debn\u00FDch modalit. Bevacizumab je potentn\u00ED antiangiogenn\u00ED l\u00E1tka, kter\u00E1 je \u00FA\u010Dinn\u00E1 v l\u00E9\u010Db\u011B mnoha solidn\u00EDch n\u00E1dor\u016F. T\u0159i velk\u00E9 randomizovan\u00E9 klinick\u00E9 studie (E2100, AVADO a RIBBON 1) prok\u00E1zaly \u00FA\u010Dinnost kombinace chemoterapie, hlavn\u011B taxan\u016F a bevacizumabu v prvn\u00ED linii l\u00E9\u010Dby metastatick\u00E9ho karcinomu prsu. Pacientky l\u00E9\u010Den\u00E9 kombinac\u00ED chemoterapie a bevacizumabu vykazovaly signifikantn\u011B del\u0161\u00ED dobu p\u0159e\u017Eit\u00ED bez progrese onemocn\u011Bn\u00ED a bez vlivu bevacizumabu na zn\u00E1mou toxicitu chemoterapie. Kombinace m\u016F\u017Ee b\u00FDt \u00FA\u010Dinnou l\u00E9\u010Debnou mo\u017Enost\u00ED hlavn\u011B u pacientek s triple negativn\u00EDm karcinomem prsu a dobrou alternativou kombinovan\u00E9 chemoterapie s mo\u017Enou ni\u017E\u0161\u00ED toxicitou." . "Avastin in the treatment of breast cancer"@en . . "1"^^ . "Petr\u00E1kov\u00E1, Katar\u00EDna" . . "I, Z(MZ0MOU2005)" . "Pacientky s metastatick\u00FDm karcinomem prsu p\u0159e\u017E\u00EDvaj\u00ED v posledn\u00EDch desetilet\u00EDch signifikantn\u011B d\u00E9le, a to hlavn\u011B d\u00EDky nov\u00FDm l\u00E9\u010Debn\u00FDm mo\u017Enostem. Chemoterapie je jednou z hlavn\u00EDch l\u00E9\u010Debn\u00FDch modalit. Bevacizumab je potentn\u00ED antiangiogenn\u00ED l\u00E1tka, kter\u00E1 je \u00FA\u010Dinn\u00E1 v l\u00E9\u010Db\u011B mnoha solidn\u00EDch n\u00E1dor\u016F. T\u0159i velk\u00E9 randomizovan\u00E9 klinick\u00E9 studie (E2100, AVADO a RIBBON 1) prok\u00E1zaly \u00FA\u010Dinnost kombinace chemoterapie, hlavn\u011B taxan\u016F a bevacizumabu v prvn\u00ED linii l\u00E9\u010Dby metastatick\u00E9ho karcinomu prsu. Pacientky l\u00E9\u010Den\u00E9 kombinac\u00ED chemoterapie a bevacizumabu vykazovaly signifikantn\u011B del\u0161\u00ED dobu p\u0159e\u017Eit\u00ED bez progrese onemocn\u011Bn\u00ED a bez vlivu bevacizumabu na zn\u00E1mou toxicitu chemoterapie. Kombinace m\u016F\u017Ee b\u00FDt \u00FA\u010Dinnou l\u00E9\u010Debnou mo\u017Enost\u00ED hlavn\u011B u pacientek s triple negativn\u00EDm karcinomem prsu a dobrou alternativou kombinovan\u00E9 chemoterapie s mo\u017Enou ni\u017E\u0161\u00ED toxicitou."@cs .